Blueprint Medicines
168 articles about Blueprint Medicines
-
Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis
1/28/2022
Positive opinion based on results from two clinical trials that comprise the largest clinical trial dataset in advanced systemic mastocytosis.
-
Blueprint Medicines Elevates Two Talented Leaders to its Executive Team
1/20/2022
Blueprint Medicines Corporation today announced two executive leadership changes highlighting the company's commitment to developing exceptional leaders.
-
Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership
1/10/2022
Blueprint Medicines Corporation (NASDAQ: BPMC) today outlined upcoming portfolio milestones that are anticipated to extend its position as a leading precision therapy company.
-
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 06, 2022
1/6/2022
Blueprint Medicines Corporation announced that, effective on January 1, 2022, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 9,725 shares of its common stock and an aggregate of 4,862 restricted stock units to seven new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines Announces CEO and Leadership Transition Plan
1/5/2022
Blueprint Medicines Corporation announced that its Board of Directors has appointed Kate Haviland to succeed Jeff Albers as Chief Executive Officer, effective April 4, 2022.
-
Several biopharma companies have adjusted their leadership teams to include new chief executive officers who are expected to guide the companies and their programs into the future.
-
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Dec 07, 2021
12/7/2021
Blueprint Medicines Corporation announced that, effective on December 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 39,862 shares of its common stock and an aggregate of 19,930 restricted stock units to thirteen new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
11/29/2021
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has entered into a definitive agreement under which it will acquire Lengo Therapeutics.
-
The deal adds LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations, to its pipeline.
-
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Nov 05, 2021
11/5/2021
Blueprint Medicines Corporation announced that, effective on November 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 24,373 shares of its common stock and an aggregate of 12,183 restricted stock units to eighteen new employees under Blueprint Medicines' 2020 Inducement Plan.
-
Blueprint Medicines Reports Third Quarter 2021 Financial Results
10/28/2021
Blueprint Medicines Corporation today reported financial results and provided a business update for the third quarter ended September 30, 2021.
-
Blueprint Medicines to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021
10/21/2021
Blueprint Medicines Corporation today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 28, 2021 to report its third quarter 2021 financial results and provide a corporate update.
-
Blueprint Medicines Reports Second Quarter 2021 Financial Results
7/29/2021
Blueprint Medicines Corporation reported financial results and provided a business update for the second quarter ended June 30, 2021.
-
Blueprint, MD Anderson Cancer Center Accelerate Research Partnership To Develop Cancer Therapies
7/28/2021
The research will focus on accelerating the capacities of BLU-222, an investigational therapy that Blueprint designed to target cyclin-dependent kinase 2 (CDK2). -
Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
7/22/2021
Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday , July 29, 2021 to report its second quarter 2021 financial results and provide a corporate update.
-
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 07, 2021
7/7/2021
Blueprint Medicines Corporation announced that, effective on July 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 25,762 shares of its common stock and an aggregate of 12,880 restricted stock units to 12 new employees under Blueprint Medicines' 2020 Inducement Plan.
-
The U.S. FDA approved Ayvakit for the treatment of adult patients with advanced sytematic mastocytosis (SM), advanced SM, and mast cell leukemia.
-
The month of June continues to be busy for the U.S. Food and Drug Administration. There are three PDUFA dates on the calendar for this week. Here’s a look.
-
Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Advanced Solid Tumors
5/19/2021
88% ORR and median duration of response not reached in treatment-naïve patients with non-small cell lung cancer enrolled after expansion of trial inclusion criteria to include patients eligible for standard-of-care front-line therapy
-
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 05, 2021
5/5/2021
Blueprint Medicines Corporation announced that, effective on May 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 21,045 shares of its common stock and an aggregate of 10,520 restricted stock units to 13 new employees under Blueprint Medicines' 2020 Inducement Plan.